GlassScriptPhysician profile
Walter Scott Waugh
NPI 1669531604
$8,819.09
in general payments reported to CMS, 2019-2025
74 companies · $849 in 2025
The $849 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,419 · 2020: $1,041 · 2021: $1,739 · 2022: $1,559 · 2023: $1,367 · 2024: $846 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,032 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,032.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,598.37 | 2019-2024 | Vraylar, Qulipta, Botox |
| Novo Nordisk INC | $841.86 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $561.60 | 2020-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $556.52 | 2019-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $520.31 | 2023-2025 | |
| Amgen INC. | $309.45 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $300.35 | 2019-2025 | Mounjaro, Trulicity |
| Ibsa Pharma INC. | $280.07 | 2019-2023 | Tirosint, Licart |
| Corcept Therapeutics | $219.68 | 2023-2025 | Korlym |
| Antares Pharma, INC. | $208.94 | 2019-2025 | Xyosted |
| Corium, LLC | $198.58 | 2021-2024 | Azstarys |
| Allergan, INC. | $170.93 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.91 | 2019-2025 | Jardiance, Ofev |
| Sunovion Pharmaceuticals INC. | $148.84 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.74 | 2019-2021 |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Waugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.